Currently Dr Reddy’s, Cipla and Zydus derive significant portion of their earnings from generic Revlimid; Realisations on generic Revlimid can fall in second half of ...

Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...

Nomura cited higher contribution from diabetes drug Sitaglitptin, which offers a market size of around $300-400 million to be the biggest factor in Zydus Life's rating upgrade.

Currently, Nomura is factoring in a 5% decline in US revenues for Zydus Life in financial year 2026, in comparison to ...